279 related articles for article (PubMed ID: 36571267)
21. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination.
Gao R; Zheng C; Yang M; Dai L; Chen C; Yao J; Zhang Z; Tang L; Shi Y; Han X
Expert Rev Vaccines; 2023; 22(1):1102-1113. PubMed ID: 37878494
[TBL] [Abstract][Full Text] [Related]
23. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
[TBL] [Abstract][Full Text] [Related]
24. Antibody response to inactivated COVID-19 vaccine in patients with type 2 diabetes mellitus after the booster immunization.
Li H; Wang Y; Li X; Wang S; Feng X; Xiao X; Li Y
J Diabetes; 2023 Nov; 15(11):931-943. PubMed ID: 37518861
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.
Overheu O; Lendowski S; Quast DR; Kühn D; Vidal Blanco E; Kraeft AL; Steinmann E; Kourti E; Lugnier C; Steinmann J; Reinacher-Schick A; Pfaender S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10633-10644. PubMed ID: 37300723
[TBL] [Abstract][Full Text] [Related]
26. Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.
Vanetti C; Stracuzzi M; Crivellaro E; Ciciliano F; Garziano M; Fenizia C; Biasin M; Rubinacci V; Amendola A; Tanzi E; Zuccotti GV; Clerici M; Giacomet V; Trabattoni D
Front Immunol; 2023; 14():1301766. PubMed ID: 38250079
[TBL] [Abstract][Full Text] [Related]
27. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
[TBL] [Abstract][Full Text] [Related]
28. The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus.
Matsumoto Y; Murata M; Ohta A; Yamasaki S; Ikezaki H; Toyoda K; Shimono N
J Infect Chemother; 2024 May; 30(5):417-422. PubMed ID: 37977325
[TBL] [Abstract][Full Text] [Related]
29. No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study).
Kling KD; Janulis P; Demonbreun AR; Sancilio A; Berzins B; Krueger K; Achenbach C; Price R; Sullivan M; Caputo M; Hockney S; Zembower T; McDade TW; Taiwo B
Front Immunol; 2022; 13():1048776. PubMed ID: 36700200
[TBL] [Abstract][Full Text] [Related]
30. Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV.
Marchitto L; Chatterjee D; Ding S; Gendron-Lepage G; Tauzin A; Boutin M; Benlarbi M; Medjahed H; Sylla M; Lanctôt H; Durand M; Finzi A; Tremblay C
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896781
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
32. Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV.
Ngare I; Tan TS; Toyoda M; Kuwata T; Takahama S; Nakashima E; Yamasaki N; Motozono C; Fujii T; Minami R; Barabona G; Ueno T
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675897
[TBL] [Abstract][Full Text] [Related]
33. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
34. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
35. Durable natural killer cell response after three doses of SARS-CoV-2 inactivated vaccine in HIV-infected individuals.
Yang X; Wang X; Zhang X; Ding H; Wang H; Huang T; Zhang G; Duan J; Xia W; Su B; Jin C; Wu H; Zhang T
Chin Med J (Engl); 2023 Dec; 136(24):2948-2959. PubMed ID: 38018259
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 vaccine immunogenicity for people living with HIV: A systematic review and meta-analysis.
Søndergaard MH; Thavarajah JJ; Churchill Henson H; Wejse CM
HIV Med; 2024 Jan; 25(1):16-37. PubMed ID: 37731375
[TBL] [Abstract][Full Text] [Related]
37. Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV.
Zou S; Guo W; Wu S; Ming F; Tan Y; Wu M; Tang W; Liang K
Front Immunol; 2022; 13():988304. PubMed ID: 36325346
[TBL] [Abstract][Full Text] [Related]
38. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
Front Immunol; 2022; 13():966098. PubMed ID: 35979361
[TBL] [Abstract][Full Text] [Related]
39. Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort.
Zeng G; He F; Zhang X; Li G; Wang X; Gan Y; Zheng C; Tang J; Xu L; Zhao J; Feng S; Yang Z
J Med Virol; 2023 May; 95(5):e28797. PubMed ID: 37218584
[TBL] [Abstract][Full Text] [Related]
40. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
